PL2598525T3 - Mutanty frataksyny - Google Patents

Mutanty frataksyny

Info

Publication number
PL2598525T3
PL2598525T3 PL11788225T PL11788225T PL2598525T3 PL 2598525 T3 PL2598525 T3 PL 2598525T3 PL 11788225 T PL11788225 T PL 11788225T PL 11788225 T PL11788225 T PL 11788225T PL 2598525 T3 PL2598525 T3 PL 2598525T3
Authority
PL
Poland
Prior art keywords
frataxin
mutants
frataxin mutants
Prior art date
Application number
PL11788225T
Other languages
English (en)
Inventor
Roberto Testi
Original Assignee
Roberto Testi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roberto Testi filed Critical Roberto Testi
Publication of PL2598525T3 publication Critical patent/PL2598525T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0091Oxidoreductases (1.) oxidizing metal ions (1.16)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y116/00Oxidoreductases oxidizing metal ions (1.16)
    • C12Y116/03Oxidoreductases oxidizing metal ions (1.16) with oxygen as acceptor (1.16.3)
    • C12Y116/03001Ferroxidase (1.16.3.1), i.e. ceruloplasmin
PL11788225T 2010-07-28 2011-07-27 Mutanty frataksyny PL2598525T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36857610P 2010-07-28 2010-07-28
PCT/IB2011/002511 WO2012014083A2 (en) 2010-07-28 2011-07-27 Frataxin mutants
EP11788225.8A EP2598525B1 (en) 2010-07-28 2011-07-27 Frataxin mutants

Publications (1)

Publication Number Publication Date
PL2598525T3 true PL2598525T3 (pl) 2016-03-31

Family

ID=45044630

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11788225T PL2598525T3 (pl) 2010-07-28 2011-07-27 Mutanty frataksyny

Country Status (12)

Country Link
US (2) US9217019B2 (pl)
EP (2) EP3012267A1 (pl)
CA (1) CA2806303C (pl)
DK (1) DK2598525T3 (pl)
ES (1) ES2552456T3 (pl)
HR (1) HRP20151238T1 (pl)
HU (1) HUE028111T2 (pl)
PL (1) PL2598525T3 (pl)
PT (1) PT2598525E (pl)
SI (1) SI2598525T1 (pl)
SM (1) SMT201500264B (pl)
WO (1) WO2012014083A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10442779B2 (en) 2014-09-22 2019-10-15 Fratagene Therapeutics S.R.L. Compositions and methods for treating Friedreich's ataxia
WO2016103223A1 (en) * 2014-12-23 2016-06-30 Fratagene Therapeutics Ltd. Methods of treating friedreich's ataxia using src inhibitors
US20180021364A1 (en) * 2015-01-16 2018-01-25 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
WO2017172914A1 (en) 2016-03-30 2017-10-05 Wisconsin Alumni Research Foundation Methods and compositions for modulating frataxin expression
MX2019005235A (es) * 2016-11-09 2019-12-05 Intrexon Corp Constructos de expresion de frataxina.
US11759533B2 (en) 2017-03-29 2023-09-19 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
US10426775B2 (en) 2017-09-11 2019-10-01 Fratagene Therapeutics Srl Methods for treating Friedreich's ataxia with etravirine
EP3999102A1 (en) 2019-07-18 2022-05-25 Larimar Therapeutics, Inc. Use of frataxin for treating leigh syndrome, french canadian type
BR112022001657A2 (pt) 2019-07-29 2022-03-22 Univ Indiana Trustees Polipeptídeo de fusão, sequência de ácidos nucleicos, cassete de expressão, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para tratar a ataxia de friedreich e para tratar uma doença associada à ataxia de friedreich
CA3176208A1 (en) 2020-04-30 2021-11-04 Joan David Bettoun Methods for treating myelin associated diseases and mitochondria associated diseases
IL303607A (en) 2020-12-12 2023-08-01 Larimar Therapeutics Inc A pharmaceutical preparation that includes FRATAXIN FUSION protein and methods of using it

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
AT500929B1 (de) 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
US8703749B2 (en) * 2009-12-07 2014-04-22 Roberto Testi Compositions and methods for treating Friedreich's Ataxia

Also Published As

Publication number Publication date
SMT201500264B (it) 2016-01-08
US9217019B2 (en) 2015-12-22
US20160060605A1 (en) 2016-03-03
EP3012267A1 (en) 2016-04-27
DK2598525T3 (da) 2015-09-21
SI2598525T1 (sl) 2016-02-29
HUE028111T2 (en) 2016-11-28
CA2806303C (en) 2018-01-02
PT2598525E (pt) 2015-11-02
WO2012014083A2 (en) 2012-02-02
EP2598525A2 (en) 2013-06-05
CA2806303A1 (en) 2012-02-02
US9944906B2 (en) 2018-04-17
EP2598525B1 (en) 2015-08-19
HRP20151238T1 (hr) 2015-12-18
WO2012014083A3 (en) 2012-04-19
US20130196932A1 (en) 2013-08-01
ES2552456T3 (es) 2015-11-30

Similar Documents

Publication Publication Date Title
AP3607A (en) Substituted imidazopyridazines
HK1171452A1 (en) Substituted pyrrolidine-2-carboxamides -2-
SI2598525T1 (sl) Mutanti frataksina
GB201021502D0 (en) Biomarkers
GB201008340D0 (en) Biomarkers
HK1188782A1 (en) Substituted sodium-1h-pyrazole-5-olate 1h--5-
IL230217B (en) New mutations ecd–r17–il
GB201018056D0 (en) Biomarkers
GB201005561D0 (en) Biomarkers
GB201001444D0 (en) Biomarkers
GB201004442D0 (en) Biomarker
EP2554994A4 (en) BIOMARKERS
GB201103569D0 (en) Mutants
GB201010316D0 (en) Biomarkers
GB201005456D0 (en) Biomarkers
EP2588088A4 (en) SOLID SHAPES
GB201001419D0 (en) Biomarkers
GB2487707B (en) Sliding gauge
GB201008727D0 (en) Biomarkers
GB201021504D0 (en) Biomarkers
GB201021498D0 (en) Biomarkers
GB201005563D0 (en) Biomarkers
GB201007919D0 (en) Biomarker
PL392421A1 (pl) Kształtownik
GB201015848D0 (en) Glycobiological surfaces